Page 21 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

List of Contributors xix

Saika Sharmeen, D.O.
College of Osteopathic Medicine
New York Institute of Technology
Old Westbury, New York, USA
Central Nervous System Vasculitis Due to Drug Abuse (Chapter 28)

Rona M. Smith, M.D.
Addenbrooke?s Hospital
Cambridge University Hospitals
University of Cambridge School of Clinical Medicine
National Health Service Foundation Trust
Cambridge, United Kingdom
Future Directions of Therapeutic Trials (Chapter 33)

Robert F. Spiera, M.D.
Scleroderma, Vasculitis & Myositis Center
Department of Medicine
Division of Rheumatology
Hospital for Special Surgery
New York, New York, USA
Rheumatoid Arthritis Vasculitis (Chapter 16)

Antoine Sreih, M.D.
Department of Medicine
University of Pennsylvania
8th Floor Penn Tower
3400 Spruce Street
Philadelphia, Pennsylvania, USA
Overview of the Treatment of Primary Systemic Vasculitis (Chapter 32)

Benjamin Terrier, M.D.
Department of Internal Medicine
National Reference Center for Rare Autoimmune and Systemic Diseases
INSERM U1060
Hôpital Cochin, Assistance Publique–Hôpitaux de Paris
University of Paris 5-René-Descartes, Paris Cedex 14, France
Immunosuppressant Medications Employed in Primary Systemic Vasculitides (Chapter 31)

Jennifer A. Tracy, M.D.
Peripheral Neuropathy Research Center
Mayo Clinic
Rochester, Minnesota, USA
Peripheral Nerve Vasculitis: Classification and Disease Associations (Chapter 29)

Complimentary Contributor Copy